842 related articles for article (PubMed ID: 12766882)
21. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
[TBL] [Abstract][Full Text] [Related]
23. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P
Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796
[TBL] [Abstract][Full Text] [Related]
24. Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies.
Park SJ; Min WS; Yang IH; Kim HJ; Min CK; Eom HS; Kim DW; Han CW; Lee JW; Kim CC
Korean J Intern Med; 2000 Dec; 15(3):224-31. PubMed ID: 11242811
[TBL] [Abstract][Full Text] [Related]
25. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy.
Ballen KK; Becker PS; Emmons RV; Fitzgerald TJ; Hsieh CC; Liu Q; Heyes C; Clark Y; Levy W; Lambert JF; Chiafari F; Szymanski I; Rososhansky S; Popovsky MA; Stewart FM; Quesenberry PJ
Blood; 2002 Jul; 100(2):442-50. PubMed ID: 12091334
[TBL] [Abstract][Full Text] [Related]
26. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.
Kothari S; Artz AS; Lee SM; Fulton N; Park JH; Stock W; Larson RA; Odenike O; Kline J; LaBelle J; Kosuri S; Riedell P; Nakamura Y; Bishop MR; Liu H
Bone Marrow Transplant; 2020 Jun; 55(6):1161-1168. PubMed ID: 31992847
[TBL] [Abstract][Full Text] [Related]
27. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
[TBL] [Abstract][Full Text] [Related]
28. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation.
Nagler A; Or R; Naparstek E; Varadi G; Slavin S
Exp Hematol; 2000 Sep; 28(9):1096-104. PubMed ID: 11008023
[TBL] [Abstract][Full Text] [Related]
29. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
30. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation.
Dey BR; McAfee S; Colby C; Cieply K; Caron M; Saidman S; Preffer F; Shaffer J; Tarbell N; Sackstein R; Sachs D; Sykes M; Spitzer TR
Br J Haematol; 2005 Feb; 128(3):351-9. PubMed ID: 15667537
[TBL] [Abstract][Full Text] [Related]
32. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
Soiffer RJ; Alyea EP; Hochberg E; Wu C; Canning C; Parikh B; Zahrieh D; Webb I; Antin J; Ritz J
Biol Blood Marrow Transplant; 2002; 8(11):625-32. PubMed ID: 12463482
[TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
Saito TI; Rubio MT; Sykes M
Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
[TBL] [Abstract][Full Text] [Related]
34. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
Chan GW; Gorgun G; Miller KB; Foss FM
Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
[TBL] [Abstract][Full Text] [Related]
36. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743
[TBL] [Abstract][Full Text] [Related]
37. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
38. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Marks DI; Lush R; Cavenagh J; Milligan DW; Schey S; Parker A; Clark FJ; Hunt L; Yin J; Fuller S; Vandenberghe E; Marsh J; Littlewood T; Smith GM; Culligan D; Hunter A; Chopra R; Davies A; Towlson K; Williams CD
Blood; 2002 Nov; 100(9):3108-14. PubMed ID: 12384406
[TBL] [Abstract][Full Text] [Related]
39. Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter.
Ros-Soto J; Snowden JA; Szydlo R; Nicholson E; Madrigal A; Easdale S; Potter M; Ethell M; Anthias C
Transplant Cell Ther; 2022 Apr; 28(4):183.e1-183.e8. PubMed ID: 35104660
[TBL] [Abstract][Full Text] [Related]
40. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
Jillella AP; Shafer D; Klumpp TR; Emmons RV; Mangan KF
Am J Hematol; 2007 Jun; 82(6):419-26. PubMed ID: 17211845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
